1. Scrip
  2. >>Business
  3. >>Financing

A Vaccines Renaissance, Spurred By COVID-19, Is Underway

 
• By Jessica Merrill

The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.

Sun Rise
The outlook for vaccines is bright • Source: Alamy

Vaccines are a hot area of development and investment, spurred by renewed awareness of the critical public health role they play and the enormous commercial success of the COVID-19 vaccines that have reached the market. Leaders at the Biotechnology Innovation Organization annual meeting agreed there is renewed interest in the field from a wide range of industry stakeholders as the COVID-19 pandemic has reset the outlook for the business area.

"I probably went two to three years without seeing a vaccines business plan. I'm probably seeing two to three a week now," SVB Leerink director of therapeutics research Geoff Porges said during a panel discussion of the vaccines business outlook

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

More from Business